Reactivation of latent HIV-1 by new semi-synthetic ingenol esters

Virology

Volumn 462-463, Issue 1, 2014, Pages 328-339

  Pandeló José, Diego ^a   Bartholomeeusen, Koen ^b   da Cunha, Rodrigo Delvecchio ^a   Abreu, Celina Monteiro ^a   Glinski, Jan ^c   da Costa, Thais Barbizan Ferreira ^d   Bacchi Rabay, Ana Flávia Mello ^d   Pianowski Filho, Luiz Francisco ^d   Dudycz, Lech W ^e   Ranga, Udaykumar ^f   Peterlin, Boris Matija ^b   Pianowski, Luiz Francisco ^d   Tanuri, Amilcar ^a   Aguiar, Renato Santana ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Planta Analytica LLC   (United States)

^d Kyolab Laboratories   (Brazil)

^e Lex Company Research Laboratories   (United States)

^f JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

HIV; Ingenol; Latency; NF kB; P TEFb; PKC; Resting cells

Indexed keywords

3 CAPROYL INGENOL; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; HEXAMETHYLENEBISACETAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INGENOL 3 CINNAMATE; INGENOL 3 DODECANOATE; INGENOL 3,20 DIBENZOATE; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VORINOSTAT;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TRANSPORT; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; UPREGULATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSCRIPTION;

HIV; INGENOL; LATENCY; NF-KB; P-TEFB; PKC; RESTING CELLS;

CELL LINE; DITERPENES; ESTERS; HIV-1; HUMANS; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84907288256     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.05.033     Document Type: Article

References (68)

1. Aditya S., Gupta S. Ingenol mebutate: a novel topical drug for actinic keratosis. Indian Dermatol. Online J. 2013, 4:246-249. 10.4103/2229-5178.115538.
2. Archin N.M., Espeseth A., Parker D., Cheema M., Hazuda D., Margolis D.M. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retrovir. 2009, 25:207-212. 10.1089/aid.2008.0191.
3. Archin N.M., Liberty a L., Kashuba a D., Choudhary S.K., Kuruc J.D., Crooks a M., Parker D.C., Anderson E.M., Kearney M.F., Strain M.C., Richman D.D., Hudgens M.G., Bosch R.J., Coffin J.M., Eron J.J., Hazuda D.J., Margolis D.M. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485. 10.1038/nature11286.
4. Bachu M., Yalla S., Asokan M., Verma A., Neogi U., Sharma S., Murali R.V, Mukthey A.B., Bhatt R., Chatterjee S., Rajan R.E., Cheedarla N., Yadavalli V.S., Mahadevan A., Shankar S.K., Rajagopalan N., Shet A., Saravanan S., Balakrishnan P., Solomon S., Vajpayee M., Satish K.S., Kundu T.K., Jeang K.-T., Ranga U. Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J. Biol. Chem. 2012, 287:44714-44735. 10.1074/jbc.M112.397158.
5. Bartholomeeusen K., Fujinaga K., Xiang Y., Peterlin B.M. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J. Biol. Chem. 2013, 288:14400-14407. 10.1074/jbc.M113.464834.
6. Bullen C.K., Laird G.M., Durand C.M., Siliciano J.D., Siliciano R.F. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 2014, 20:425-429. 10.1038/nm.3489.
7. Burnett J.C., Lim K.-I., Calafi A., Rossi J.J., Schaffer D.V, Arkin A.P. Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol. 2010, 84:5958-5974. 10.1128/JVI.00161-10.
8. Cho W.-K., Jang M.K., Huang K., Pise-Masison C.a, Brady J.N. Human T-lymphotropic virus type 1 Tax protein complexes with P-TEFb and competes for Brd4 and 7SK snRNP/HEXIM1 binding. J. Virol. 2010, 84:12801-12809. 10.1128/JVI.00943-10.
9. Contreras X., Barboric M., Lenasi T., Peterlin B.M. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 2007, 3:1459-1469. 10.1371/journal.ppat.0030146.
10. Contreras X., Mzoughi O., Gaston F., Peterlin M.B., Bahraoui E. Protein kinase C-delta regulates HIV-1 replication at an early post-entry step in macrophages. Retrovirology 2012, 9:37. 10.1186/1742-4690-9-37.
11. Contreras X., Schweneker M., Chen C.-S., McCune J.M., Deeks S.G., Martin J., Peterlin B.M. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 2009, 284:6782-6789. 10.1074/jbc.M807898200.
12. Dahabieh M.S., Ooms M., Brumme C., Taylor J., Harrigan P.R., Simon V., Sadowski I. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB. Retrovirology 2014, 11:17. 10.1186/1742-4690-11-17.
13. Desfosses Y., Solis M., Sun Q., Grandvaux N., Lint C., Van, Burny A., Gatignol A., Wainberg M.A., Lin R., Hiscott J. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific tat proteins. J. Virol. 2005, 79:9180-9191. 10.1128/JVI.79.14.9180.
14. Dong Q., Kelkar S., Xiao Y., Joshi-Barve S., McClain C.J., Barve S.S. Ethanol enhances TNF-alpha-inducible NFkappaB activation and HIV-1-LTR transcription in CD4+ Jurkat T lymphocytes. J. Lab. Clin. Med. 2000, 136:333-343. 10.1067/mlc.2000.110104.
15. Ersvaer E., Kittang A.O., Hampson P., Sand K., Gjertsen B.T., Lord J.M., Bruserud O. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins (Basel) 2010, 2:174-194. 10.3390/toxins2010174.
16. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300. (80). 10.1126/science.278.5341.1295.
17. Friedman J., Cho W.-K., Chu C.K., Keedy K.S., Archin N.M., Margolis D.M., Karn J. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J. Virol. 2011, 85:9078-9089. 10.1128/JVI.00836-11.
18. Fujiwara M., Okamoto M., Ijichi K., Tokuhisa K., Hanasaki Y., Katsuura K., Uemura D., Shigeta S., Konno K., Yokota T., Baba M. Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives Brief Report. Arch. Virol. 1998, 143:2003-2010.
19. Ganesh L., Burstein E., Guha-Niyogi A., Louder M.K., Mascola J.R., Klomp L.W.J., Wijmenga C., Duckett C.S., Nabel G.J. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 2003, 426:853-857. 10.1038/nature02171.
20. Geeraert L., Kraus G., Pomerantz R.J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 2008, 59:487-501. 10.1146/annurev.med.59.062806.123001.
21. González E., Punzón C., González M., Fresno M. HIV-1 tat inhibits IL-2 gene transcription through qualitative and quantitative alterations of the cooperative Rel/AP1 complex bound to the CD28RE/AP1 composite element of the IL-2 promoter. J. Immunol. 2001, 166:4560-4569.
22. Hong K.-J., Lee H.S., Kim Y.-S., Kim S.S. Ingenol protects human T cells from HIV-1 infection. Osong Public Heal. Res. Perspect. 2011, 2:109-114. 10.1016/j.phrp.2011.07.001.
23. Hoque M., Shamanna R.A., Guan D., Pe'ery T., Mathews M.B. HIV-1 replication and latency are regulated by translational control of cyclin T1. J. Mol. Biol. 2011, 410:917-932. 10.1016/j.jmb.2011.03.060.HIV-1.
24. Huang J., Wang F., Argyris E., Chen K., Liang Z., Tian H., Huang W., Squires K., Verlinghieri G., Zhang H. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 2007, 13:1241-1247. 10.1038/nm1639.
25. Ishida T., Hamano A., Koiwa T., Watanabe T. 5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology 2006, 3:69. 10.1186/1742-4690-3-69.
26. Jassbi A.R. Chemistry and biological activity of secondary metabolites in Euphorbia from Iran. Phytochemistry 2006, 67:1977-1984. 10.1016/j.phytochem.2006.06.030.
27. Johnston R. HIV cure: controversy, consensus, and a consortium. AIDS Res. Hum. Retrovir. 2010, 26:943-946. 10.1089/aid.2010.0087.
28. Jones K.A., Peterlin B.M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 1994, 63:717-743.
29. Jordan A., Bisgrove D., Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003, 22:1868-1877. 10.1093/emboj/cdg188.
30. Karn J., Stoltzfus C.M. Regulation of HIV-1 gene expression. Cold Spring Harb. Perspect. Med. 2012, 2:1-17.
31. Khalaf H., Jass J., Olsson P.-E. Differential cytokine regulation by NF-kappaB and AP-1 in Jurkat T-cells. BMC Immunol. 2010, 11:26. 10.1186/1471-2172-11-26.
32. Kinoshita S., Su L., Amano M., Timmerman L.a, Kaneshima H., Nolan G.P. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997, 6:235-244.
33. Lassen K.G., Ramyar K.X., Bailey J.R., Zhou Y., Siliciano R.F. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog. 2006, 2:650-661. 10.1371/journal.ppat.0020068.
34. Lee W.-Y., Hampson P., Coulthard L., Ali F., Salmon M., Lord J.M., Scheel-Toellner D. Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta. J. Biol. Chem. 2010, 285:23889-23898. 10.1074/jbc.M109.041962.
35. Li L., Shukla S., Lee A., Garfield S.H., Maloney D.J., Suresh V., Yuspa S.H. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010, 70:4509-4519. 10.1158/0008-5472.CAN-09-4303.The.
36. Liu Y., Denlinger C.E., Rundall B.K., Smith P.W., Jones D.R. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J. Biol. Chem. 2006, 281:31359-31368. 10.1074/jbc.M604478200.
37. Maioli E., Fortino V. Protein kinase C: a target for anticancer drugs?. Endocr. Relat. Cancer 2004, 11:161-162.
38. Mbonye U., Karn J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 2014, 454-455C:328-339. 10.1016/j.virol.2014.02.008.
39. McKernan L.N., Momjian D., Kulkosky J. Protein Kinase C: one pathway towards the eradication of latent HIV-1 reservoirs. Adv. Virol. 2012, 2012:1-8. 10.1155/2012/805347.
40. Mochly-Rosen D., Gordon A.S. Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J. 1998, 12:35-42.
41. Montano M.a., Nixon C.P., Ndung'u T., Bussmann H., Novitsky V.a., Dickman D., Essex M. Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. J. Infect. Dis. 2000, 181:76-81. 10.1086/315185.
42. Naghavi M.H., Schwartz S., Sönnerborg a., Vahlne a. Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1. AIDS Res. Hum. Retrovir. 1999, 15:1293-1303. 10.1089/088922299310197.
43. Olsnes A.M., Ersvaer E., Ryningen A., Paulsen K., Hampson P., Lord J.M., Gjertsen B.T., Kristoffersen E.K., Bruserud Ø. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br. J. Haematol. 2009, 145:761-774. 10.1111/j.1365-2141.2009.07691.x.
44. Opijnen T.Van, Jeeninga R.E., Boerlijst M.C., Pollakis G.P., Zetterberg V., Salminen M., Berkhout B. Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J. Virol. 2004, 78:3675-3683. 10.1128/JVI.78.7.3675.
45. Pierson T., Hoffman T.L., Blankson J., Finzi D., Chadwick K., Margolick J.B., Buck C., Siliciano J.D., Doms R.W., Siliciano R.F. Characterization of Chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J. Virol. 2000, 74:7824-7833. 10.1128/JVI.74.17.7824-7833.2000.Updated.
46. Racke F.K., Baird M., Barth R.F., Huo T., Yang W., Gupta N., Weldon M., Rutledge H. Unique in vitro and in vivo thrombopoietic activities of ingenol 3,20 dibenzoate, a Ca(++)-independent protein kinase C isoform agonist. PLoS One 2012, 7:e51059. 10.1371/journal.pone.0051059.
47. Remoli A.L., Marsili G., Battistini A., Sgarbanti M. The development of immune-modulating compounds to disrupt HIV latency. Cytokine Growth Factor Rev. 2012, 23:159-172. 10.1016/j.cytogfr.2012.05.003.
48. Reuse S., Calao M., Kabeya K., Guiguen A., Gatot J.-S., Quivy V., Vanhulle C., Lamine A., Vaira D., Demonte D., Martinelli V., Veithen E., Cherrier T., Avettand V., Poutrel S., Piette J., de Launoit Y., Moutschen M., Burny A., Rouzioux C., De Wit S., Herbein G., Rohr O., Collette Y., Lambotte O., Clumeck N., Van Lint C Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009, 4:e6093. 10.1371/journal.pone.0006093.
49. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection can we do better than HAART?. Science 2009, 323:1304-1307.
50. Roof P., Ricci M., Genin P., Montano M.a, Essex M., Wainberg M.a, Gatignol A., Hiscott J. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology 2002, 296:77-83. 10.1006/viro.2001.1397.
51. Rossenkhan R., MacLeod I.J., Sebunya T.K., Castro-Nallar E., McLane M.F., Musonda R., Gashe B.a, Novitsky V., Essex M. tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection. J. Virol. 2013, 87:5732-5745. 10.1128/JVI.03297-12.
52. Routy J.P., Tremblay C.L., Angel J.B., Trottier B., Rouleau D., Baril J.G., Harris M., Trottier S., Singer J., Chomont N., Sékaly R.P., Boulassel M.R. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012, 13:291-296. 10.1111/j.1468-1293.2011.00975.x.
53. Sahu G.K., Cloyd M.W. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Virol. J. 2011, 8:400-406. 10.1186/1743-422X-8-400.
54. Salatino A., Salatino M.L.F., Negri G. Traditional uses, chemistry and pharmacology of Croton species ( Euphorbiaceae ). J. Braz. Chem. Soc. 2007, 18:11-33.
55. Sgarbanti M., Remoli A.L., Marsili G., Ridolfi B., Borsetti A., Perrotti E., Orsatti R., Ilari R., Sernicola L., Stellacci E., Ensoli B., Battistini A. IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J. Virol. 2008, 82:3632-3641. 10.1128/JVI.00599-07.
56. Song X., Lopez-Campistrous A., Sun L., Dower N.a, Kedei N., Yang J., Kelsey J.S., Lewin N.E., Esch T.E., Blumberg P.M., Stone J.C. RasGRPs are targets of the anti-cancer agent ingenol-3-angelate. PLoS One 2013, 8:e72331. 10.1371/journal.pone.0072331.
57. Spitaler M., Cantrell D.a. Protein kinase C and beyond. Nat. Immunol. 2004, 5:785-790. 10.1038/ni1097.
58. Steinberg S.F. Structural basis of protein Kinase C isoform function. Physiol. Rev. 2008, 88:1341-1378. 10.1152/physrev.00034.2007.
59. Strair R.K., Schaar D., Goodell L., Aisner J., Chin K., Eid J., Senzon R., Cui X.X., Han Z.T., Knox B., Rabson A.B., Chang R., Conney A. Administration of a Phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res. 2002, 2512-2518. (Administration of a Phorbol Ester to Patients with Hematological Malignancies: Preli).
60. Torgerson T.R., Colosia a D., Donahue J.P., Lin Y.Z., Hawiger J. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J. Immunol. 1998, 161:6084-6092.
61. Tyagi M., Pearson R.J., Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 2010, 84:6425-6437. 10.1128/JVI.01519-09.
62. Van Lint C., Bouchat S., Marcello A. HIV-1 transcription and latency: an update. Retrovirology 2013, 10:67. 10.1186/1742-4690-10-67.
63. Warrilow D., Gardner J., Darnell G.a, Suhrbier A., Harrich D. HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res. Hum. Retrovir. 2006, 22:854-864. 10.1089/aid.2006.22.854.
64. Williams S.A., Chen L.-F., Kwon H., Fenard D., Bisgrove D., Verdin E., Greene W.C. Prostratin antagonizes HIV latency by activating NF-kappaB. J. Biol. Chem. 2004, 279:42008-42017. 10.1074/jbc.M402124200.
65. Williams S.A., Chen L.-F., Kwon H., Ruiz-Jarabo C.M., Verdin E., Greene W.C. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 2006, 25:139-149. 10.1038/sj.emboj.7600900.
66. Wu C., Liu F., Zhou X., Cheng Z., Yang X., Xiao H., Chen Q., Cai K. Effect of protein kinase C on proliferation and apoptosis of T lymphocytes in idiopathic thrombocytopenic purpura children. Cell. Mol. Immunol. 2005, 2:197-203.
67. Yang H., Xing S., Shan L., Connell K.O., Dinoso J., Shen A., Zhou Y., Shrum C.K., Han Y., Liu J.O., Zhang H., Margolick J.B., Siliciano R.F. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 2009, 119:3473-3486. 10.1172/JCI39199DS1.
68. Yang X., Chen Y., Gabuzda D. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappa B. J. Biol. Chem. 1999, 274:27981-27988. 10.1074/jbc.274.39.27981.